TP53 and cancer: When we compared the frequency of RB1/TP53 co-mutants by sample type (primary vs. metastasis) (Figure S6), we observed many of the cancer types with co-mutants enriched in the dead patients also have co-mutants enriched in the metastatic samples, such as prostate adenocarcinoma, lung adenocarcinoma, and pancreatic adenocarcinoma.